Evaluating radiotherapy guided by MRI technology
Official title: Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment
Run by Institute of Cancer Research, United Kingdom · NCT03727698 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new type of radiotherapy that uses MRI technology to see if it can improve treatment results and reduce side effects for patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 5 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Institute of Cancer Research, United Kingdom Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT03727698 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 5 to 16 who require radiotherapy suitable for delivery on the MR linac.
✕Probably not a fit
Patients with contraindications to MR imaging or those whose radiotherapy needs exceed the capabilities of the MR linac will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to gather data on patients receiving radiotherapy using a new machine that incorporates magnetic resonance imaging (MR linac) to enhance treatment precision. By collecting information on treatment outcomes and side effects, the study seeks to inform the integration of MR linac into standard clinical practice. The data will be combined with information from other centers using this technology to optimize future radiotherapy protocols.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized cancer treatment with fewer side effects.
How similar studies have gone: Other studies using MR-guided radiotherapy have shown promise, indicating potential for success with this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Radiotherapy treatment suitable to be delivered on the MR Linac. 2. Patient provides written, informed consent and/or authorization. 3. Patients between the ages of 5 and under 16 years old may enter protocol with parental/guardian consent. Exclusion Criteria: 1. Contra-indications to MR imaging. 2. Radiotherapy not suitable for delivery on the MR Linac e.g. those with extended field lengths (exceeding 20 cm).
Where it's running
-
Royal Marsden NHSFT
London, United Kingdom Recruiting
Study contacts
- Study coordinator: Robert Huddart
- Email: robert.huddart@icr.ac.uk
- Phone: 44 208 661 3425
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how genetic mutations affect cancer treatment response in advanced solid tumours
This study tests whether mutations found in tumor and blood samples can help predict who will benefit from early-phase cancer treatments.
-
Bexmarilimab plus nivolumab in solid tumors, melanoma, and NSCLC
This trial tests whether adding bexmarilimab to nivolumab can help people with melanoma, non-small cell lung cancer, or other advanced solid tumors whose cancer stopped responding to immune therapy.
-
BALANCE: Understanding Quality of Life for Black and Mixed Men with Prostate Cancer
This study tests how prostate cancer and its treatments affect quality of life for Black men of African or Caribbean ancestry and men of mixed Black ancestry.
-
Paxalisib plus temozolomide for malignant brain tumours with PI3K pathway changes
This trial tests whether adding paxalisib to standard temozolomide helps people with newly diagnosed MGMT-unmethylated glioblastoma whose tumors have PI3K-activating mutations or PTEN loss.
-
SX-682 combined with apalutamide for advanced prostate cancer no longer responding to hormone therapy.
This trial will test whether adding SX-682 to apalutamide helps men with metastatic castration‑resistant prostate cancer who have progressed after another next‑generation antiandrogen.
-
Idetrexed plus olaparib for high-grade serous ovarian cancer
This trial tests whether combining idetrexed and olaparib helps people with high-grade serous ovarian cancer that is resistant to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.